The biotechnology industry will grow considerably in the next two decades. Dr. Lindsay A. Rosenwald believes in responding to the need for safe effective remedies with medical improvements developed by his companies. Dr. Rosenwald’s discoveries will lead to the effectual treatment of diseases, such as cancer and heart disease. Dr. Rosenwald knows that inventive technologies will be developed by the small-scale biotechnology and life-science companies. Dr. Rosenwald has developed select group of products, bringing concentrated focus to those products and securing their favorable stance in the biotechnological field.
Dr. Rosenwald has been the leader and developer of many companies. He is the President of the Rosenwald Foundation, a benevolent association in New York which supports remarkable scientific individuals in their constant efforts to further the progress of biotechnology. The Rosenwald Foundation has also contributed millions to many notable schools and institutions. Dr. Rosenwald is also affiliated with the Columbia-Presbyterian Health Sciences Advisory Counsel. The Columbia Presbyterian Health Sciences Advisory Council presents two Awards for Distinguished Services yearly to mavericks who have made a great impact on the community’s health and welfare.
Dr. Lindsay A. Rosenwald attained his medical degree from Temple University School of Medicine in 1983. He has been key in the creation and intercontinental expansion of numerous public and private biotechnology and life-science companies since then. Dr. Rosenwald has a Bachelor of Science degree in finance from Pennsylvania State University. He has been a trailblazer in the world of biotechnology on Wall Street for over 20 years. Dr. Rosenwald was a Physician Analysts on Wall Street in 1986. He is believed to be one of the world’s most productive entrepreneurs in the history of the biotechnological industry.
Dr. Lindsay A. Rosenwald has been a prosperous pharmaceutical and biotechnology financier for over a decade. His skills originated within his extensive pharmaceutical/biomedical business and investment experience. Such experience includes investment banking, venture capital, merchant banking and asset management. Dr. Rosenwald has given many careers for MDs, PhDs, MBAs, attorneys and related professionals.
Dr. Rosenwald holds the record for the most capital ever paid for a medication that was not yet finalized in clinical development. In 2009 Cougar Biotechnology, company founded by Dr. Rosenwald, was sold to Johnson and Johnson for a unprecedented 1 billion dollars. The transaction hinged on a medication that had completed phase 2 in clinical trials for prostate cancer but had not yet completed phase 3 in clinical trials. A cancer drug to treat a rare form of deadly leukemia created by PolaRx BioPharmaceuticals received final marketing authorization only 30 months after the first patient was treated in a clinical trial, setting a record for the biotechnology industry. Dr. Rosenwald’s companies have changed the biotechnology industry and will continue to change the industry in the years to come.